The Shu complex prevents mutagenesis and cytotoxicity of single-strand specific alkylation lesions

  1. Braulio Bonilla
  2. Alexander I Brown
  3. Sarah R Hengel
  4. Kyle S Rapchak
  5. Debra Mitchell
  6. Catherine A Pressimone
  7. Adeola A Fagunloye
  8. Thong T Luong
  9. Reagan A Russell
  10. Rudri K Vyas
  11. Tony M Mertz
  12. Hani S Zaher
  13. Nima Mosammaparast
  14. Ewa P Malc
  15. Piotr A Mieczkowski
  16. Steven Roberts  Is a corresponding author
  17. Kara A Bernstein  Is a corresponding author
  1. University of Pittsburgh School of Medicine, United States
  2. Washington State University, United States
  3. Washington University in St Louis, United States
  4. University of North Carolina Chapel Hill, United States

Abstract

Three-methyl cytosine (3meC) are toxic DNA lesions, blocking base pairing. Bacteria and humans, express members of the AlkB enzymes family, which directly remove 3meC. However, other organisms, including budding yeast, lack this class of enzymes. It remains an unanswered evolutionary question as to how yeast repairs 3meC, particularly in single-stranded DNA. The yeast Shu complex, a conserved homologous recombination factor, aids in preventing replication-associated mutagenesis from DNA base damaging agents such as methyl methanesulfonate (MMS). We found that MMS-treated Shu complex-deficient cells, exhibit a genome-wide increase in A:T and G:C substitutions mutations. The G:C substitutions displayed transcriptional and replicational asymmetries consistent with mutations resulting from 3meC. Ectopic expression of a human AlkB homolog in Shu-deficient yeast rescues MMS-induced growth defects and increased mutagenesis. Thus, our work identifies a novel homologous recombination-based mechanism mediated by the Shu complex for coping with alkylation adducts.

Data availability

All unique mutations identified by DNA sequencing are reported in Supplemental Table 3 and all sequencing reads are reported in Supplemental Table 5. Raw sequencing reads in fastq format have been submitted to the NCBI short read archive under BioProject accession number PRJNA694993.

The following data sets were generated

Article and author information

Author details

  1. Braulio Bonilla

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Alexander I Brown

    Molecular Biosciences, Washington State University, Pullman, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Sarah R Hengel

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Kyle S Rapchak

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Debra Mitchell

    Molecular Biosciences, Washington State University, Pullman, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Catherine A Pressimone

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Adeola A Fagunloye

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2383-9469
  8. Thong T Luong

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Reagan A Russell

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Rudri K Vyas

    Molecular Biosciences, Washington State University, Pullman, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Tony M Mertz

    Molecular Biosciences, Washington State University, Pullman, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Hani S Zaher

    Biology, Washington University in St Louis, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7424-3617
  13. Nima Mosammaparast

    Washington University in St Louis, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Ewa P Malc

    Genetics, University of North Carolina Chapel Hill, Chapel Hill, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Piotr A Mieczkowski

    Genetics, University of North Carolina Chapel Hill, Chapel Hill, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Steven Roberts

    Molecular Biosciences, Washington State University, Pullman, United States
    For correspondence
    steven.roberts2@wsu.edu
    Competing interests
    The authors declare that no competing interests exist.
  17. Kara A Bernstein

    Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States
    For correspondence
    karab@pitt.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2247-6459

Funding

National Institutes of Health (ES030335)

  • Kara A Bernstein

National Institutes of Health (CA218112)

  • Steven Roberts

American Cancer Society (129182-RSG-16-043-01-DMC)

  • Kara A Bernstein

American Cancer Society (133947-PF-19-132-01-DMC)

  • Sarah R Hengel

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Bonilla et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,331
    views
  • 171
    downloads
  • 4
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Braulio Bonilla
  2. Alexander I Brown
  3. Sarah R Hengel
  4. Kyle S Rapchak
  5. Debra Mitchell
  6. Catherine A Pressimone
  7. Adeola A Fagunloye
  8. Thong T Luong
  9. Reagan A Russell
  10. Rudri K Vyas
  11. Tony M Mertz
  12. Hani S Zaher
  13. Nima Mosammaparast
  14. Ewa P Malc
  15. Piotr A Mieczkowski
  16. Steven Roberts
  17. Kara A Bernstein
(2021)
The Shu complex prevents mutagenesis and cytotoxicity of single-strand specific alkylation lesions
eLife 10:e68080.
https://doi.org/10.7554/eLife.68080

Share this article

https://doi.org/10.7554/eLife.68080

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Angel D'Oliviera, Xuhang Dai ... Jeffrey S Mugridge
    Research Article

    The SARS-CoV-2 main protease (Mpro or Nsp5) is critical for production of viral proteins during infection and, like many viral proteases, also targets host proteins to subvert their cellular functions. Here, we show that the human tRNA methyltransferase TRMT1 is recognized and cleaved by SARS-CoV-2 Mpro. TRMT1 installs the N2,N2-dimethylguanosine (m2,2G) modification on mammalian tRNAs, which promotes cellular protein synthesis and redox homeostasis. We find that Mpro can cleave endogenous TRMT1 in human cell lysate, resulting in removal of the TRMT1 zinc finger domain. Evolutionary analysis shows the TRMT1 cleavage site is highly conserved in mammals, except in Muroidea, where TRMT1 is likely resistant to cleavage. TRMT1 proteolysis results in reduced tRNA binding and elimination of tRNA methyltransferase activity. We also determined the structure of an Mpro-TRMT1 peptide complex that shows how TRMT1 engages the Mpro active site in an uncommon substrate binding conformation. Finally, enzymology and molecular dynamics simulations indicate that kinetic discrimination occurs during a later step of Mpro-mediated proteolysis following substrate binding. Together, these data provide new insights into substrate recognition by SARS-CoV-2 Mpro that could help guide future antiviral therapeutic development and show how proteolysis of TRMT1 during SARS-CoV-2 infection impairs both TRMT1 tRNA binding and tRNA modification activity to disrupt host translation and potentially impact COVID-19 pathogenesis or phenotypes.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Qian Wang, Jinxin Liu ... Qian Liu
    Research Article

    Paramyxovirus membrane fusion requires an attachment protein for receptor binding and a fusion protein for membrane fusion triggering. Nipah virus (NiV) attachment protein (G) binds to ephrinB2 or -B3 receptors, and fusion protein (F) mediates membrane fusion. NiV-F is a class I fusion protein and is activated by endosomal cleavage. The crystal structure of a soluble GCN4-decorated NiV-F shows a hexamer-of-trimer assembly. Here, we used single-molecule localization microscopy to quantify the NiV-F distribution and organization on cell and virus-like particle membranes at a nanometer precision. We found that NiV-F on biological membranes forms distinctive clusters that are independent of endosomal cleavage or expression levels. The sequestration of NiV-F into dense clusters favors membrane fusion triggering. The nano-distribution and organization of NiV-F are susceptible to mutations at the hexamer-of-trimer interface, and the putative oligomerization motif on the transmembrane domain. We also show that NiV-F nanoclusters are maintained by NiV-F–AP-2 interactions and the clathrin coat assembly. We propose that the organization of NiV-F into nanoclusters facilitates membrane fusion triggering by a mixed population of NiV-F molecules with varied degrees of cleavage and opportunities for interacting with the NiV-G/receptor complex. These observations provide insights into the in situ organization and activation mechanisms of the NiV fusion machinery.